{"ticker": {"uuid": "45864420-8158-4459-a5ae-679989408c7c", "symbol": "AMRN", "name": "Amarin Corporation PLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/amarin-report-second-quarter-2026-120000623.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:00:00+00:00", "published_display": "15 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOODdLcFg1dHZzN1Z4TG1XaGJ3cDZrUnIzd04tczRNVWs0ODJYaTMyRnVmSkl2SnlaYjlKd05oQ0ZlYzVsV014X1lPVU53cEstWS1aLURPMmRiUnZCUVR2Mks0S2VTQVhhaEYwclVZR0g5dE1TbFRxcklfUnFhTUhETWczVVFwMFlaQUxCWDdYOGFpMnp2M1d5aGoySk5nQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T13:55:01+00:00", "published_display": "10 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming (NASDAQ:AMRN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNVDFtWHJqV1hzYmVJaDVqbGgxZ0p5MTNLU1F1azNzRzd4N2phR3ZSV1J1MzlDeGI4X2FnazdaRklMWDZzNklUZlkydWxtQ0dxTnZtLXk0d1M2QkJXckJia2tLY2hSMFVldmN1T1RHQU5vSWlkLXBzblk0V0R6NnJ2VE9hcDRTZmw3MkZPWWtWQ1BQNjZ5NEttXzFvRDR1amIxa09OZ3hudlFrcGMtcmJxaVBn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-07T12:58:10+00:00", "published_display": "07 Jul 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMRN - Amarin Corp ADR Options", "summary": "This article provides a detailed financial overview of Amarin Corp ADR (AMRN), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It presents a snapshot of the company's valuation, profitability, and stock volatility, alongsid", "url": "https://finviz.com/stock?t=AMRN&ty=oc&ov=chain_strike&s=15", "source_name": "Finviz", "published_at": "2026-07-06T12:40:09", "published_display": "06 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Corp PLC (AMRN) Stock Forecast, Price Targets and Analysts Predictions", "summary": "This article provides a stock forecast, price targets, and analyst predictions for Amarin Corp PLC (AMRN). It highlights the company's market capitalization, enterprise value, and various financial ratios, offering a comprehensive overview for potential investors. The data is sou", "url": "https://www.gurufocus.com/stock/AMRN/forecast?r=caf6fe0e0db70d936033da5461e60141&utm_source=yahoo_finance&utm_medium=syndication&utm_campaign=headlines&utm_content=earnings_to_watch%3A_amarin_corp_plc_%28amrn%29_reports_q3_2025_results&utm_term=AMRN", "source_name": "GuruFocus", "published_at": "2026-07-03T12:39:48", "published_display": "03 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMRN - Amarin Corp ADR Volatility & Greeks", "summary": "The article provides a detailed financial snapshot of Amarin Corp ADR (AMRN), including its volatility, Greek values, performance metrics, and key financial ratios. It lists various financial data points like market cap, sales, EPS, insider ownership, and price performance over d", "url": "https://finviz.com/stock?t=AMRN&p=d&ty=ocv&r=m3&ov=list_strike&s=16", "source_name": "Finviz", "published_at": "2026-07-03T12:10:18", "published_display": "03 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin highlights VASCEPA's proven role and affordability in treating severe hypertriglyceridemia amid new therapies.", "summary": "Amarin Corporation has emphasized the continued importance of VASCEPA (icosapent ethyl) for treating severe hypertriglyceridemia (sHTG), despite the emergence of new injectable APOC3 therapies. The company highlights VASCEPA's strong clinical benefits, including a 33% median trig", "url": "https://pluang.com/en/news-feed/amarin-tegaskan-peran-vascepa-dalam-perawatan-trigliserida", "source_name": "Pluang", "published_at": "2026-07-02T11:39:50", "published_display": "02 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMARIN (AMRN) CEO Berg exercises RSUs as ADSs, 3,197 shares withheld for tax", "summary": "AMARIN (AMRN) CEO Aaron Berg reported routine equity compensation, converting 6,250 Restricted Stock Units (RSUs) into American Depositary Shares (ADSs). To cover tax liabilities from this vesting, 3,197 ADSs were withheld by the issuer at $16.35 per ADS. Following these transact", "url": "https://www.stocktitan.net/sec-filings/AMRN/form-4-amarin-corp-plcuk-insider-trading-activity-62f37d56e2f1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:10:09", "published_display": "01 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin says VASCEPA remains a first-line option as triglyceride drugs expand", "summary": "Amarin (NASDAQ: AMRN) is reaffirming VASCEPA's role as a first-line treatment for severe hypertriglyceridemia (sHTG) amidst the approval of new injectable APOC3 therapies. The company highlights VASCEPA's proven efficacy in reducing triglycerides by 33% and cardiovascular events ", "url": "https://www.stocktitan.net/news/AMRN/amarin-reaffirms-the-proven-guideline-recommended-role-of-vascepa-etkjk8sw5nla.html", "source_name": "Stock Titan", "published_at": "2026-07-01T07:10:09", "published_display": "01 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA\u00ae (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape", "summary": "Amarin Corporation plc highlights the continued importance of its product, VASCEPA (icosapent ethyl), in the treatment of severe hypertriglyceridemia (sHTG) and elevated triglycerides, especially following the FDA approval of new injectable APOC3 therapies. The company emphasizes", "url": "https://finance.yahoo.com/healthcare/articles/amarin-reaffirms-proven-guideline-recommended-201500305.html", "source_name": "Market source", "published_at": "2026-06-30T20:42:14", "published_display": "30 Jun 2026 20:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?", "summary": "Amarin (AMRN) is outperforming the Medical sector and its specific industry (Medical - Biomedical and Genetics) with a year-to-date return of 6.8% compared to the sector's 3.6% loss and the industry's 1.2% loss. The company holds a Zacks Rank #2 (Buy), driven by a significant 85.", "url": "https://ca.finance.yahoo.com/news/amarin-amrn-outperforming-other-medical-134003995.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-12T09:40:00", "published_display": "12 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Supreme Court Clarifies Pleading Standard for Induced Infringement in Hikma v. Amarin", "summary": "The Supreme Court recently clarified the pleading standard for induced patent infringement, particularly in cases involving \"skinny labels\" for generic drugs. In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the Court unanimously held that a branded drug patent owner mus", "url": "https://www.jdsupra.com/legalnews/supreme-court-clarifies-pleading-1688159/", "source_name": "JD Supra", "published_at": "2026-06-10T16:38:55", "published_display": "10 Jun 2026 16:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma v. Amarin and a Clarified Standard for Induced Patent Infringement Under 35 U.S.C. \u00a7 271(b)", "summary": "The Supreme Court recently clarified the standard for induced patent infringement under 35 U.S.C. \u00a7 271(b) in the case of Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., setting a higher bar for plaintiffs. The Court ruled that a complaint must plausibly allege that the de", "url": "https://natlawreview.com/article/hikma-v-amarin-and-clarified-standard-induced-patent-infringement-under-35-usc-ss", "source_name": "The National Law Review", "published_at": "2026-06-09T22:40:47", "published_display": "09 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma v. Amarin: Supreme Court Reins in Induced Infringement Claims Against Skinny Label Generic Drugs", "summary": "The U.S. Supreme Court has limited induced infringement claims against skinny label generic drugs in the case of Hikma v. Amarin. The court ruled that Amarin failed to plausibly allege that Hikma actively encouraged doctors to infringe on its CV-indication patents for VASCEPA, de", "url": "https://natlawreview.com/article/hikma-v-amarin-supreme-court-reins-induced-infringement-claims-against-skinny-label", "source_name": "The National Law Review", "published_at": "2026-06-05T18:09:14", "published_display": "05 Jun 2026 18:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics", "summary": "The Supreme Court has upheld the use of \"skinny labels\" for generic drugs, a decision that deals a blow to Amarin. This ruling confirms that generic drug manufacturers can omit certain patented uses from their labels without infringing on a brand-name drug's patent. Amarin, which", "url": "https://www.msn.com/en-us/money/companies/amarin-dealt-blow-as-supreme-court-upholds-skinny-labels-for-generics/ar-AA24QNAZ?gemSnapshotKey=GMBC6A178A-snapshot-43&uxmode=ruby&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-05T17:10:42", "published_display": "05 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Supreme Court Clarifies Standard for Induced Infringement in Hikma v. Amarin | Mintz - Intellectual Property Viewpoints", "summary": "The Supreme Court, in a unanimous decision, clarified the standard for induced patent infringement in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. The Court ruled that \"skinny label\" generic drug manufacturers do not induce infringement simply by commercially equating ge", "url": "https://www.jdsupra.com/legalnews/supreme-court-clarifies-standard-for-7304393/", "source_name": "JD Supra", "published_at": "2026-06-05T14:10:42", "published_display": "05 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Supreme Court Unanimously Rules Against Induced Infringement Claims Based on Routine Generic Drug Marketing", "summary": "The Supreme Court unanimously ruled in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. that routine generic drug marketing activities, such as skinny labels and standard therapeutic equivalence descriptions, do not automatically constitute active inducement of patent infrin", "url": "https://www.mcguirewoods.com/client-resources/alerts/2026/6/supreme-court-unanimously-rules-against-induced-infringement-claims-based-on-routine-generic-drug-marketing/", "source_name": "McGuireWoods", "published_at": "2026-06-05T09:39:48", "published_display": "05 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNNWMySlVuRkNic0gydnk0c3E5Mi03NWVnZEp3Zm5YWWV4Y05vb3JYQkQ3cVlZenp2N1VNZ2x5eVRQUVVMOV95NkpmVHhQLUdYenpQbU1HUC04Y1hyLXJjdnQyak92M2ZRRm8zQTlvRHdnQXMwWm9LczZIMHJZNFl2dTdPeGdPY2c1cmhJYU5EZGJGdw?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Supreme Court backs generic fish-oil drug in Hikma-Amarin case", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNZE1lZC1tcUU1YmlsRzYyVHJONlRXYWswYk00VUVJc1NpWVFPaC1JNDZHeU14U0kzaVZna0xVS2V2UEpJRnk1TFAySmxCWEpSLWZkU1dQc20zcWlQeTZLLVd6aTBxNEZPZ1dlNVI5THo2WkNhUGgwbFdWc0J0NDVlTFhFUDVxVlpqaW8yTzQzUjRURmwxUUx0clRyNERCaWpoRXU1cFk3c19IbnhLanN2UXpfTXFZaWM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMRN - Amarin Corp ADR Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial data for Amarin Corp ADR (AMRN), a pharmaceutical company focused on cardiovascular health. It includes various financial metrics, insider and institutional ownership, performance indicators, and a comprehensive list of a", "url": "https://finviz.com/stock?t=AMRN", "source_name": "Finviz", "published_at": "2026-06-02T20:42:14", "published_display": "02 Jun 2026 20:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Amarin (AMRN) Story Is Shifting With A Refined Fair Value And Outlook", "summary": "Amarin (AMRN) has seen its target fair value refined from US$12.00 to US$12.50 per share due to updated analyst views on execution and long-term growth. The article details both bullish and bearish analyst arguments, highlighting factors such as stable shipment guidance, producti", "url": "https://finance.yahoo.com/markets/stocks/articles/amarin-amrn-story-shifting-refined-021615928.html", "source_name": "Market source", "published_at": "2026-05-22T04:10:45", "published_display": "22 May 2026 04:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Corporation plc Files Form 8-K Detailing Company Information and Security Registration (May 2026)", "summary": "Amarin Corporation plc's Annual General Meeting on May 13, 2026, saw several key proposals regarding share issuance, stock incentive plans, and corporate governance fail to pass. This outcome limits the company's ability to issue equity incentives to employees, potentially leadin", "url": "https://www.minichart.com.sg/2026/05/15/amarin-corporation-plc-files-form-8-k-detailing-company-information-and-security-registration-may-2026/", "source_name": "Minichart", "published_at": "2026-05-15T17:09:59", "published_display": "15 May 2026 17:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin shareholders reject key proposals at annual meeting, limit equity grants", "summary": "Amarin shareholders rejected several key proposals at their Annual General Meeting, including those related to director reelections, executive compensation advisory approval, and share issuance authorizations. As a result, the company's ability to grant equity incentives will be ", "url": "https://www.investing.com/news/sec-filings/amarin-shareholders-reject-key-proposals-at-annual-meeting-limit-equity-grants-93CH-4691719", "source_name": "Investing.com", "published_at": "2026-05-15T11:09:59", "published_display": "15 May 2026 11:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin (NASDAQ: AMRN) investors curb new share issues and limit equity pay tools", "summary": "Amarin Corporation plc shareholders rejected several key capital and governance proposals at their Annual General Meeting, including the authorization to issue new shares, an increase in the stock incentive plan, and the disapplication of pre-emption rights. This decision severel", "url": "https://www.stocktitan.net/sec-filings/AMRN/8-k-amarin-corp-plcuk-reports-material-event-c3f2b2a319ac.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:09:11", "published_display": "15 May 2026 10:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObEc5YlZlclR2em1hdWtZM3V1S2lDUnZfTWhxTWFIY1FweUU5VzM3b25oMjdrSkItN2ZDTVNpcXRsOWhqWU5wOUx6RU1FZ3hXQzEtZkpqUmJyNVlBNXMtV09qZ3o4QmwzU1A4T2k3RTR6NjYySnVITEFhcHZvVExPNGV6aGRzTmV5Z28yZXV1RjRUNElOUmZ2OFZXRjc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin says overseas sales and cost cuts kept cash flow positive", "summary": "Amarin (NASDAQ: AMRN) reported a 7% increase in Q1 2026 total net revenue to $45.1 million, driven by international sales and licensing. The company achieved positive cash flow for the second consecutive quarter and reiterated expectations for full-year 2026 positive cash flow, m", "url": "https://www.stocktitan.net/news/AMRN/amarin-reports-2026-first-quarter-financial-snwzu0cl0qbi.html", "source_name": "Stock Titan", "published_at": "2026-05-04T08:40:41", "published_display": "04 May 2026 08:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin's Q1 loss narrower than expected, sales increase Y/Y", "summary": "Amarin (AMRN) reported a narrower-than-expected loss in Q1, with sales increasing year-over-year. The company's financial performance showed improvement, indicating positive trends in its operations.", "url": "https://www.msn.com/en-us/money/topstocks/amarin-s-q1-loss-narrower-than-expected-sales-increase-y-y/ar-AA227n0v", "source_name": "MSN", "published_at": "2026-05-03T12:10:44", "published_display": "03 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Corp PLC (AMRN) Q1 2026 Earnings Call Highlights: Revenue Growth and Market Expansion ... By GuruFocus", "summary": "Amarin Corp PLC (AMRN) reported strong Q1 2026 results, showing a second consecutive quarter of positive cash flow, a significantly narrowed operating loss, and increased U.S. market share for VASCEPA. Despite facing generic competition in the U.S., the company achieved revenue g", "url": "https://ca.investing.com/news/company-news/amarin-corp-plc-amrn-q1-2026-earnings-call-highlights-revenue-growth-and-market-expansion--4597774", "source_name": "Investing.com Canada", "published_at": "2026-05-02T09:39:32", "published_display": "02 May 2026 09:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Corporation plc (NASDAQ:AMRN) Q1 2026 Earnings Call Transcript", "summary": "Amarin Corporation plc announced its Q1 2026 earnings, reporting a miss on EPS expectations but showcasing continued momentum in its new business model and global restructuring efforts, leading to positive cash flow for the second consecutive quarter. The company highlighted stro", "url": "https://www.insidermonkey.com/blog/amarin-corporation-plc-nasdaqamrn-q1-2026-earnings-call-transcript-1752058/", "source_name": "Insider Monkey", "published_at": "2026-05-02T07:09:22", "published_display": "02 May 2026 07:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin (AMRN) Loss Trend Of 24.2% Annually Tests Turnaround Narratives Heading Into Q1", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How a Supreme Court fight over fish oil could raise your prescription drug costs", "summary": "The Supreme Court is hearing the case of Hikma v. Amarin, which could significantly impact the cost of prescription drugs. The dispute revolves around \"skinny labeling,\" a strategy allowing generic drugs to enter the market faster for unpatented uses. A ruling against generic dru", "url": "https://www.npr.org/2026/04/29/nx-s1-5803137/supreme-court-generic-drugs-hikma", "source_name": "NPR", "published_at": "2026-04-29T18:09:14", "published_display": "29 Apr 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMARIN ($AMRN) Releases Q1 2026 Earnings | AMRN Stock News", "summary": "AMARIN ($AMRN) reported its Q1 2026 earnings, missing earnings per share estimates but beating revenue expectations. The company posted -$0.09 EPS on revenue of $45,130,000. Institutional investors showed mixed activity, with 31 adding and 34 decreasing their positions in AMARIN ", "url": "https://www.quiverquant.com/news/AMARIN+%28%24AMRN%29+Releases+Q1+2026+Earnings", "source_name": "Quiver Quantitative", "published_at": "2026-04-29T12:55:00", "published_display": "29 Apr 2026 12:55", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Amarin Q1 2026 shows revenue growth amid restructuring", "summary": "Amarin Corporation (AMRN) reported strong Q1 2026 results, with total net revenue increasing by 7.4% year-over-year to $45.1 million, driven by strategic restructuring and international partnerships. The company significantly reduced operating expenses by 31%, narrowing its opera", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-amarin-q1-2026-shows-revenue-growth-amid-restructuring-93CH-4645044", "source_name": "Investing.com", "published_at": "2026-04-29T12:39:31", "published_display": "29 Apr 2026 12:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin: Q1 Earnings Snapshot", "summary": "Amarin Corp. PLC (AMRN) reported a first-quarter loss of $10.5 million, or 60 cents per share. After adjustments for restructuring and non-recurring costs, the loss was 9 cents per share. The biopharmaceutical company recorded revenues of $45.1 million for the period, and its sto", "url": "https://www.kens5.com/article/syndication/associatedpress/amarin-q1-earnings-snapshot/616-98848b8c-69c8-4689-a820-7509451e8251", "source_name": "kens5.com", "published_at": "2026-04-29T12:39:31", "published_display": "29 Apr 2026 12:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Reports 2026 First Quarter Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQRHY3d3NwMzluUTlTTkV4WVlTandRbFR1M00yZ25mVmZVbVp5VG10eGtvQU83RktkZ1N4TGxrYkxjS2ZxSXlLNXBMLUhJOWRteFVGS0s2NWp3Ulo0b3pzM2t3Rzl3UDdiQXJRMzJGWmNreXc5MHNEaVJCd0RHX3lzSmZicUN6RXc0X1dkdWNUVG1hR0lNdUd3ZXZ2UmUwaUd6Y1lXcg?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin (NASDAQ: AMRN) trims Q1 2026 losses with 7% revenue growth and cost cuts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNQlJuSHUyU0swbGpnQ0JtZUtndnpHTTB2U3c0TlN6ZnZ6X242a3FXa0todlY0ckN1bVJqSk5wRktZRE1zQUEtbzNSb0pHaEdiQ18ySEFyU1pDdTBDSFQ0bFJMeHdOUXhMckN4VzZhaDRWdThmUlZmT0VJYWRvZXk4aS1LbVp3T1g4cEpZUnBGQ29Xd3ZlODBhYkNnZmlpT0dJOEJPMzhxQmJVc1U?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Amarin (AMRN) Story Is Shifting With An Unchanged US$12 Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQSGxTNW1mQldTZVNaeVNKYVB3WWV3Xzk2Zm1Lc3VISXRsUnZxeVZwS2kxSW1ZMWtWRHJ2MThVUmp2dUM4R2l3aGM5RDExT3B0X2VxclhtdHNIQ01LRHVodnRNRUVqLXRtZy0xaG5laERpanBUZUUycFBrTDlkay1FdkM2QnZkcjdtQXVLSTdHbFQyMDFrZlFLZVFRZ0J0czBObWN3?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOQXN3VGlPak1neE1ScGVBNnkxdTk1dHdXYnJtTzlEclljYm9TNTlRaTVIbFkzZmNHZDhWSDNiNWxUaE9lZThtblVxMHcyc1JzbUN6VW1HVy14dW1pVzd5UG4yMmRDUFNGUXplbzdHcHJFZllxTU1KbVNvQzNKczIyb1hIZVU0UEZwWWlwdmlxZUI5TmI5QlZzNHl6S00zbkRr?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why I Wouldn't Touch Amarin With a 10\u2011Foot Pole Given Its Patent and Competition Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPNXVkYTVVQXNyeHZVemgwMnd1MmpUMFhNR3NMTTdrTHY4TmVYdU8zUHk3SlRfamtvdVB2cHBVRVdWUnZsYklGYm02STFDYy1ZOVVxUkM5R0hkSWFyZjliWGRkM0FJdUFkd1NwdHROeXJJNkp4em13ck5Db3RxeUQ2c1BTWS0zTmtJWmFIOHBmTFpWdnN4bmNvZw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-07T08:00:00+00:00", "published_display": "07 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin down as topline contracts in Q4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNNDhCdWt1SnVET3dHMWpIMDlqRmtaQnJjaVQ2VDg4Y1RBRFFYZG5YeThRemYzU1BZV3NMRWZlWEVtbE5EcUtvU1NZcU52Tk0tdUw4R09MRVA5eVl2SWNBSVh4NlpaWWs3WUhKV0UyQWJUM0N6OFZFeVB0bTh0TUhrZTR3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin (AMRN): Deep Discount Reinforces Market Caution Despite Projected Earnings Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOWFBGOW5lZUozR29YdDlmeG5makhtSkdhTzNXWm9qWlA5eWUwVkxBVGZVc0loSVhVTlpFR3Q1eWctWlU2VlNENXctWVRpSVhqeGM0bTNNV3pNbVc2a1BBZm1fWHZYanB1NFVCblJOWi1QM3BzalYtMHZtTWQ0WjczLWRZRGZLNkRZTmc?oc=5", "source_name": "Market source", "published_at": "2025-10-31T07:00:00+00:00", "published_display": "31 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom (NASDAQ:AMRN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOVXZrazczQUVuMDFOSFlpbzRXUkZGRTByZk40cFZYNzRIWThoWWZHdkxaRFVGbFBBS25HRWNwZElpNkRqWElsME9NdlpJZC14R3JtbjdGYkJpQV8ybjFuVEVBS3VZcWNra0JMVUM4SFAzVU15bUNHOHNfMWVjZnZrSDluOXNqUHotREc2S1NXR0xQOWZidUdkTlpSQzEyMk56UGNNc09uZkdfZmNh?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin sells heart pill Vascepa's rights in Europe to Recordati amid restructuring bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTjBNdnRvcnBXTk5wbDRMS2JqZkR0UWMzU2FVMENPQ3BUeGFpSnVVLWRpWGVmbjlDSS1nYXBqSXh2b25XMnY1amhVaExiMElfcDFPenloTGMwX0FVczMzVGNqeDhyMkI5ckdFcGh0WVl2cUFSZ1JFS24yWmc3RDRBWV96Tzk0TXBjeGU2NHpreWxYeG1LWGw0ZmZOem5Cb0wtSTd3?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-06-24T07:00:00+00:00", "published_display": "24 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/amarin-report-second-quarter-2026-120000623.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:00:00+00:00", "published_display": "15 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOODdLcFg1dHZzN1Z4TG1XaGJ3cDZrUnIzd04tczRNVWs0ODJYaTMyRnVmSkl2SnlaYjlKd05oQ0ZlYzVsV014X1lPVU53cEstWS1aLURPMmRiUnZCUVR2Mks0S2VTQVhhaEYwclVZR0g5dE1TbFRxcklfUnFhTUhETWczVVFwMFlaQUxCWDdYOGFpMnp2M1d5aGoySk5nQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T13:55:01+00:00", "published_display": "10 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming (NASDAQ:AMRN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNVDFtWHJqV1hzYmVJaDVqbGgxZ0p5MTNLU1F1azNzRzd4N2phR3ZSV1J1MzlDeGI4X2FnazdaRklMWDZzNklUZlkydWxtQ0dxTnZtLXk0d1M2QkJXckJia2tLY2hSMFVldmN1T1RHQU5vSWlkLXBzblk0V0R6NnJ2VE9hcDRTZmw3MkZPWWtWQ1BQNjZ5NEttXzFvRDR1amIxa09OZ3hudlFrcGMtcmJxaVBn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-07T12:58:10+00:00", "published_display": "07 Jul 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMRN - Amarin Corp ADR Options", "summary": "This article provides a detailed financial overview of Amarin Corp ADR (AMRN), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It presents a snapshot of the company's valuation, profitability, and stock volatility, alongsid", "url": "https://finviz.com/stock?t=AMRN&ty=oc&ov=chain_strike&s=15", "source_name": "Finviz", "published_at": "2026-07-06T12:40:09", "published_display": "06 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Corp PLC (AMRN) Stock Forecast, Price Targets and Analysts Predictions", "summary": "This article provides a stock forecast, price targets, and analyst predictions for Amarin Corp PLC (AMRN). It highlights the company's market capitalization, enterprise value, and various financial ratios, offering a comprehensive overview for potential investors. The data is sou", "url": "https://www.gurufocus.com/stock/AMRN/forecast?r=caf6fe0e0db70d936033da5461e60141&utm_source=yahoo_finance&utm_medium=syndication&utm_campaign=headlines&utm_content=earnings_to_watch%3A_amarin_corp_plc_%28amrn%29_reports_q3_2025_results&utm_term=AMRN", "source_name": "GuruFocus", "published_at": "2026-07-03T12:39:48", "published_display": "03 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMRN - Amarin Corp ADR Volatility & Greeks", "summary": "The article provides a detailed financial snapshot of Amarin Corp ADR (AMRN), including its volatility, Greek values, performance metrics, and key financial ratios. It lists various financial data points like market cap, sales, EPS, insider ownership, and price performance over d", "url": "https://finviz.com/stock?t=AMRN&p=d&ty=ocv&r=m3&ov=list_strike&s=16", "source_name": "Finviz", "published_at": "2026-07-03T12:10:18", "published_display": "03 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin highlights VASCEPA's proven role and affordability in treating severe hypertriglyceridemia amid new therapies.", "summary": "Amarin Corporation has emphasized the continued importance of VASCEPA (icosapent ethyl) for treating severe hypertriglyceridemia (sHTG), despite the emergence of new injectable APOC3 therapies. The company highlights VASCEPA's strong clinical benefits, including a 33% median trig", "url": "https://pluang.com/en/news-feed/amarin-tegaskan-peran-vascepa-dalam-perawatan-trigliserida", "source_name": "Pluang", "published_at": "2026-07-02T11:39:50", "published_display": "02 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMARIN (AMRN) CEO Berg exercises RSUs as ADSs, 3,197 shares withheld for tax", "summary": "AMARIN (AMRN) CEO Aaron Berg reported routine equity compensation, converting 6,250 Restricted Stock Units (RSUs) into American Depositary Shares (ADSs). To cover tax liabilities from this vesting, 3,197 ADSs were withheld by the issuer at $16.35 per ADS. Following these transact", "url": "https://www.stocktitan.net/sec-filings/AMRN/form-4-amarin-corp-plcuk-insider-trading-activity-62f37d56e2f1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:10:09", "published_display": "01 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin says VASCEPA remains a first-line option as triglyceride drugs expand", "summary": "Amarin (NASDAQ: AMRN) is reaffirming VASCEPA's role as a first-line treatment for severe hypertriglyceridemia (sHTG) amidst the approval of new injectable APOC3 therapies. The company highlights VASCEPA's proven efficacy in reducing triglycerides by 33% and cardiovascular events ", "url": "https://www.stocktitan.net/news/AMRN/amarin-reaffirms-the-proven-guideline-recommended-role-of-vascepa-etkjk8sw5nla.html", "source_name": "Stock Titan", "published_at": "2026-07-01T07:10:09", "published_display": "01 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA\u00ae (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape", "summary": "Amarin Corporation plc highlights the continued importance of its product, VASCEPA (icosapent ethyl), in the treatment of severe hypertriglyceridemia (sHTG) and elevated triglycerides, especially following the FDA approval of new injectable APOC3 therapies. The company emphasizes", "url": "https://finance.yahoo.com/healthcare/articles/amarin-reaffirms-proven-guideline-recommended-201500305.html", "source_name": "Market source", "published_at": "2026-06-30T20:42:14", "published_display": "30 Jun 2026 20:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?", "summary": "Amarin (AMRN) is outperforming the Medical sector and its specific industry (Medical - Biomedical and Genetics) with a year-to-date return of 6.8% compared to the sector's 3.6% loss and the industry's 1.2% loss. The company holds a Zacks Rank #2 (Buy), driven by a significant 85.", "url": "https://ca.finance.yahoo.com/news/amarin-amrn-outperforming-other-medical-134003995.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-12T09:40:00", "published_display": "12 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Supreme Court Clarifies Pleading Standard for Induced Infringement in Hikma v. Amarin", "summary": "The Supreme Court recently clarified the pleading standard for induced patent infringement, particularly in cases involving \"skinny labels\" for generic drugs. In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the Court unanimously held that a branded drug patent owner mus", "url": "https://www.jdsupra.com/legalnews/supreme-court-clarifies-pleading-1688159/", "source_name": "JD Supra", "published_at": "2026-06-10T16:38:55", "published_display": "10 Jun 2026 16:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma v. Amarin and a Clarified Standard for Induced Patent Infringement Under 35 U.S.C. \u00a7 271(b)", "summary": "The Supreme Court recently clarified the standard for induced patent infringement under 35 U.S.C. \u00a7 271(b) in the case of Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., setting a higher bar for plaintiffs. The Court ruled that a complaint must plausibly allege that the de", "url": "https://natlawreview.com/article/hikma-v-amarin-and-clarified-standard-induced-patent-infringement-under-35-usc-ss", "source_name": "The National Law Review", "published_at": "2026-06-09T22:40:47", "published_display": "09 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma v. Amarin: Supreme Court Reins in Induced Infringement Claims Against Skinny Label Generic Drugs", "summary": "The U.S. Supreme Court has limited induced infringement claims against skinny label generic drugs in the case of Hikma v. Amarin. The court ruled that Amarin failed to plausibly allege that Hikma actively encouraged doctors to infringe on its CV-indication patents for VASCEPA, de", "url": "https://natlawreview.com/article/hikma-v-amarin-supreme-court-reins-induced-infringement-claims-against-skinny-label", "source_name": "The National Law Review", "published_at": "2026-06-05T18:09:14", "published_display": "05 Jun 2026 18:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics", "summary": "The Supreme Court has upheld the use of \"skinny labels\" for generic drugs, a decision that deals a blow to Amarin. This ruling confirms that generic drug manufacturers can omit certain patented uses from their labels without infringing on a brand-name drug's patent. Amarin, which", "url": "https://www.msn.com/en-us/money/companies/amarin-dealt-blow-as-supreme-court-upholds-skinny-labels-for-generics/ar-AA24QNAZ?gemSnapshotKey=GMBC6A178A-snapshot-43&uxmode=ruby&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-05T17:10:42", "published_display": "05 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Supreme Court Clarifies Standard for Induced Infringement in Hikma v. Amarin | Mintz - Intellectual Property Viewpoints", "summary": "The Supreme Court, in a unanimous decision, clarified the standard for induced patent infringement in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. The Court ruled that \"skinny label\" generic drug manufacturers do not induce infringement simply by commercially equating ge", "url": "https://www.jdsupra.com/legalnews/supreme-court-clarifies-standard-for-7304393/", "source_name": "JD Supra", "published_at": "2026-06-05T14:10:42", "published_display": "05 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Supreme Court Unanimously Rules Against Induced Infringement Claims Based on Routine Generic Drug Marketing", "summary": "The Supreme Court unanimously ruled in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. that routine generic drug marketing activities, such as skinny labels and standard therapeutic equivalence descriptions, do not automatically constitute active inducement of patent infrin", "url": "https://www.mcguirewoods.com/client-resources/alerts/2026/6/supreme-court-unanimously-rules-against-induced-infringement-claims-based-on-routine-generic-drug-marketing/", "source_name": "McGuireWoods", "published_at": "2026-06-05T09:39:48", "published_display": "05 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNNWMySlVuRkNic0gydnk0c3E5Mi03NWVnZEp3Zm5YWWV4Y05vb3JYQkQ3cVlZenp2N1VNZ2x5eVRQUVVMOV95NkpmVHhQLUdYenpQbU1HUC04Y1hyLXJjdnQyak92M2ZRRm8zQTlvRHdnQXMwWm9LczZIMHJZNFl2dTdPeGdPY2c1cmhJYU5EZGJGdw?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Supreme Court backs generic fish-oil drug in Hikma-Amarin case", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNZE1lZC1tcUU1YmlsRzYyVHJONlRXYWswYk00VUVJc1NpWVFPaC1JNDZHeU14U0kzaVZna0xVS2V2UEpJRnk1TFAySmxCWEpSLWZkU1dQc20zcWlQeTZLLVd6aTBxNEZPZ1dlNVI5THo2WkNhUGgwbFdWc0J0NDVlTFhFUDVxVlpqaW8yTzQzUjRURmwxUUx0clRyNERCaWpoRXU1cFk3c19IbnhLanN2UXpfTXFZaWM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMRN - Amarin Corp ADR Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial data for Amarin Corp ADR (AMRN), a pharmaceutical company focused on cardiovascular health. It includes various financial metrics, insider and institutional ownership, performance indicators, and a comprehensive list of a", "url": "https://finviz.com/stock?t=AMRN", "source_name": "Finviz", "published_at": "2026-06-02T20:42:14", "published_display": "02 Jun 2026 20:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Amarin (AMRN) Story Is Shifting With A Refined Fair Value And Outlook", "summary": "Amarin (AMRN) has seen its target fair value refined from US$12.00 to US$12.50 per share due to updated analyst views on execution and long-term growth. The article details both bullish and bearish analyst arguments, highlighting factors such as stable shipment guidance, producti", "url": "https://finance.yahoo.com/markets/stocks/articles/amarin-amrn-story-shifting-refined-021615928.html", "source_name": "Market source", "published_at": "2026-05-22T04:10:45", "published_display": "22 May 2026 04:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Corporation plc Files Form 8-K Detailing Company Information and Security Registration (May 2026)", "summary": "Amarin Corporation plc's Annual General Meeting on May 13, 2026, saw several key proposals regarding share issuance, stock incentive plans, and corporate governance fail to pass. This outcome limits the company's ability to issue equity incentives to employees, potentially leadin", "url": "https://www.minichart.com.sg/2026/05/15/amarin-corporation-plc-files-form-8-k-detailing-company-information-and-security-registration-may-2026/", "source_name": "Minichart", "published_at": "2026-05-15T17:09:59", "published_display": "15 May 2026 17:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin shareholders reject key proposals at annual meeting, limit equity grants", "summary": "Amarin shareholders rejected several key proposals at their Annual General Meeting, including those related to director reelections, executive compensation advisory approval, and share issuance authorizations. As a result, the company's ability to grant equity incentives will be ", "url": "https://www.investing.com/news/sec-filings/amarin-shareholders-reject-key-proposals-at-annual-meeting-limit-equity-grants-93CH-4691719", "source_name": "Investing.com", "published_at": "2026-05-15T11:09:59", "published_display": "15 May 2026 11:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin (NASDAQ: AMRN) investors curb new share issues and limit equity pay tools", "summary": "Amarin Corporation plc shareholders rejected several key capital and governance proposals at their Annual General Meeting, including the authorization to issue new shares, an increase in the stock incentive plan, and the disapplication of pre-emption rights. This decision severel", "url": "https://www.stocktitan.net/sec-filings/AMRN/8-k-amarin-corp-plcuk-reports-material-event-c3f2b2a319ac.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:09:11", "published_display": "15 May 2026 10:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObEc5YlZlclR2em1hdWtZM3V1S2lDUnZfTWhxTWFIY1FweUU5VzM3b25oMjdrSkItN2ZDTVNpcXRsOWhqWU5wOUx6RU1FZ3hXQzEtZkpqUmJyNVlBNXMtV09qZ3o4QmwzU1A4T2k3RTR6NjYySnVITEFhcHZvVExPNGV6aGRzTmV5Z28yZXV1RjRUNElOUmZ2OFZXRjc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin says overseas sales and cost cuts kept cash flow positive", "summary": "Amarin (NASDAQ: AMRN) reported a 7% increase in Q1 2026 total net revenue to $45.1 million, driven by international sales and licensing. The company achieved positive cash flow for the second consecutive quarter and reiterated expectations for full-year 2026 positive cash flow, m", "url": "https://www.stocktitan.net/news/AMRN/amarin-reports-2026-first-quarter-financial-snwzu0cl0qbi.html", "source_name": "Stock Titan", "published_at": "2026-05-04T08:40:41", "published_display": "04 May 2026 08:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin's Q1 loss narrower than expected, sales increase Y/Y", "summary": "Amarin (AMRN) reported a narrower-than-expected loss in Q1, with sales increasing year-over-year. The company's financial performance showed improvement, indicating positive trends in its operations.", "url": "https://www.msn.com/en-us/money/topstocks/amarin-s-q1-loss-narrower-than-expected-sales-increase-y-y/ar-AA227n0v", "source_name": "MSN", "published_at": "2026-05-03T12:10:44", "published_display": "03 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Corp PLC (AMRN) Q1 2026 Earnings Call Highlights: Revenue Growth and Market Expansion ... By GuruFocus", "summary": "Amarin Corp PLC (AMRN) reported strong Q1 2026 results, showing a second consecutive quarter of positive cash flow, a significantly narrowed operating loss, and increased U.S. market share for VASCEPA. Despite facing generic competition in the U.S., the company achieved revenue g", "url": "https://ca.investing.com/news/company-news/amarin-corp-plc-amrn-q1-2026-earnings-call-highlights-revenue-growth-and-market-expansion--4597774", "source_name": "Investing.com Canada", "published_at": "2026-05-02T09:39:32", "published_display": "02 May 2026 09:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Corporation plc (NASDAQ:AMRN) Q1 2026 Earnings Call Transcript", "summary": "Amarin Corporation plc announced its Q1 2026 earnings, reporting a miss on EPS expectations but showcasing continued momentum in its new business model and global restructuring efforts, leading to positive cash flow for the second consecutive quarter. The company highlighted stro", "url": "https://www.insidermonkey.com/blog/amarin-corporation-plc-nasdaqamrn-q1-2026-earnings-call-transcript-1752058/", "source_name": "Insider Monkey", "published_at": "2026-05-02T07:09:22", "published_display": "02 May 2026 07:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin (AMRN) Loss Trend Of 24.2% Annually Tests Turnaround Narratives Heading Into Q1", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How a Supreme Court fight over fish oil could raise your prescription drug costs", "summary": "The Supreme Court is hearing the case of Hikma v. Amarin, which could significantly impact the cost of prescription drugs. The dispute revolves around \"skinny labeling,\" a strategy allowing generic drugs to enter the market faster for unpatented uses. A ruling against generic dru", "url": "https://www.npr.org/2026/04/29/nx-s1-5803137/supreme-court-generic-drugs-hikma", "source_name": "NPR", "published_at": "2026-04-29T18:09:14", "published_display": "29 Apr 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMARIN ($AMRN) Releases Q1 2026 Earnings | AMRN Stock News", "summary": "AMARIN ($AMRN) reported its Q1 2026 earnings, missing earnings per share estimates but beating revenue expectations. The company posted -$0.09 EPS on revenue of $45,130,000. Institutional investors showed mixed activity, with 31 adding and 34 decreasing their positions in AMARIN ", "url": "https://www.quiverquant.com/news/AMARIN+%28%24AMRN%29+Releases+Q1+2026+Earnings", "source_name": "Quiver Quantitative", "published_at": "2026-04-29T12:55:00", "published_display": "29 Apr 2026 12:55", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Amarin Q1 2026 shows revenue growth amid restructuring", "summary": "Amarin Corporation (AMRN) reported strong Q1 2026 results, with total net revenue increasing by 7.4% year-over-year to $45.1 million, driven by strategic restructuring and international partnerships. The company significantly reduced operating expenses by 31%, narrowing its opera", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-amarin-q1-2026-shows-revenue-growth-amid-restructuring-93CH-4645044", "source_name": "Investing.com", "published_at": "2026-04-29T12:39:31", "published_display": "29 Apr 2026 12:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin: Q1 Earnings Snapshot", "summary": "Amarin Corp. PLC (AMRN) reported a first-quarter loss of $10.5 million, or 60 cents per share. After adjustments for restructuring and non-recurring costs, the loss was 9 cents per share. The biopharmaceutical company recorded revenues of $45.1 million for the period, and its sto", "url": "https://www.kens5.com/article/syndication/associatedpress/amarin-q1-earnings-snapshot/616-98848b8c-69c8-4689-a820-7509451e8251", "source_name": "kens5.com", "published_at": "2026-04-29T12:39:31", "published_display": "29 Apr 2026 12:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin Reports 2026 First Quarter Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQRHY3d3NwMzluUTlTTkV4WVlTandRbFR1M00yZ25mVmZVbVp5VG10eGtvQU83RktkZ1N4TGxrYkxjS2ZxSXlLNXBMLUhJOWRteFVGS0s2NWp3Ulo0b3pzM2t3Rzl3UDdiQXJRMzJGWmNreXc5MHNEaVJCd0RHX3lzSmZicUN6RXc0X1dkdWNUVG1hR0lNdUd3ZXZ2UmUwaUd6Y1lXcg?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin (NASDAQ: AMRN) trims Q1 2026 losses with 7% revenue growth and cost cuts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNQlJuSHUyU0swbGpnQ0JtZUtndnpHTTB2U3c0TlN6ZnZ6X242a3FXa0todlY0ckN1bVJqSk5wRktZRE1zQUEtbzNSb0pHaEdiQ18ySEFyU1pDdTBDSFQ0bFJMeHdOUXhMckN4VzZhaDRWdThmUlZmT0VJYWRvZXk4aS1LbVp3T1g4cEpZUnBGQ29Xd3ZlODBhYkNnZmlpT0dJOEJPMzhxQmJVc1U?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Amarin (AMRN) Story Is Shifting With An Unchanged US$12 Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQSGxTNW1mQldTZVNaeVNKYVB3WWV3Xzk2Zm1Lc3VISXRsUnZxeVZwS2kxSW1ZMWtWRHJ2MThVUmp2dUM4R2l3aGM5RDExT3B0X2VxclhtdHNIQ01LRHVodnRNRUVqLXRtZy0xaG5laERpanBUZUUycFBrTDlkay1FdkM2QnZkcjdtQXVLSTdHbFQyMDFrZlFLZVFRZ0J0czBObWN3?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOQXN3VGlPak1neE1ScGVBNnkxdTk1dHdXYnJtTzlEclljYm9TNTlRaTVIbFkzZmNHZDhWSDNiNWxUaE9lZThtblVxMHcyc1JzbUN6VW1HVy14dW1pVzd5UG4yMmRDUFNGUXplbzdHcHJFZllxTU1KbVNvQzNKczIyb1hIZVU0UEZwWWlwdmlxZUI5TmI5QlZzNHl6S00zbkRr?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why I Wouldn't Touch Amarin With a 10\u2011Foot Pole Given Its Patent and Competition Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPNXVkYTVVQXNyeHZVemgwMnd1MmpUMFhNR3NMTTdrTHY4TmVYdU8zUHk3SlRfamtvdVB2cHBVRVdWUnZsYklGYm02STFDYy1ZOVVxUkM5R0hkSWFyZjliWGRkM0FJdUFkd1NwdHROeXJJNkp4em13ck5Db3RxeUQ2c1BTWS0zTmtJWmFIOHBmTFpWdnN4bmNvZw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-07T08:00:00+00:00", "published_display": "07 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin down as topline contracts in Q4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNNDhCdWt1SnVET3dHMWpIMDlqRmtaQnJjaVQ2VDg4Y1RBRFFYZG5YeThRemYzU1BZV3NMRWZlWEVtbE5EcUtvU1NZcU52Tk0tdUw4R09MRVA5eVl2SWNBSVh4NlpaWWs3WUhKV0UyQWJUM0N6OFZFeVB0bTh0TUhrZTR3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin (AMRN): Deep Discount Reinforces Market Caution Despite Projected Earnings Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOWFBGOW5lZUozR29YdDlmeG5makhtSkdhTzNXWm9qWlA5eWUwVkxBVGZVc0loSVhVTlpFR3Q1eWctWlU2VlNENXctWVRpSVhqeGM0bTNNV3pNbVc2a1BBZm1fWHZYanB1NFVCblJOWi1QM3BzalYtMHZtTWQ0WjczLWRZRGZLNkRZTmc?oc=5", "source_name": "Market source", "published_at": "2025-10-31T07:00:00+00:00", "published_display": "31 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom (NASDAQ:AMRN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOVXZrazczQUVuMDFOSFlpbzRXUkZGRTByZk40cFZYNzRIWThoWWZHdkxaRFVGbFBBS25HRWNwZElpNkRqWElsME9NdlpJZC14R3JtbjdGYkJpQV8ybjFuVEVBS3VZcWNra0JMVUM4SFAzVU15bUNHOHNfMWVjZnZrSDluOXNqUHotREc2S1NXR0xQOWZidUdkTlpSQzEyMk56UGNNc09uZkdfZmNh?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amarin sells heart pill Vascepa's rights in Europe to Recordati amid restructuring bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTjBNdnRvcnBXTk5wbDRMS2JqZkR0UWMzU2FVMENPQ3BUeGFpSnVVLWRpWGVmbjlDSS1nYXBqSXh2b25XMnY1amhVaExiMElfcDFPenloTGMwX0FVczMzVGNqeDhyMkI5ckdFcGh0WVl2cUFSZ1JFS24yWmc3RDRBWV96Tzk0TXBjeGU2NHpreWxYeG1LWGw0ZmZOem5Cb0wtSTd3?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-06-24T07:00:00+00:00", "published_display": "24 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 97, "total_relevant": 43, "sentiment_summary": {"positive": 14, "negative": 12, "neutral": 17, "score": 51, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 15.35, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 14.88, "latest_week": "2026-07-10", "one_week_move": -9.1, "four_week_move": -2.4, "twelve_week_move": -0.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.119667, "market_dynamics_buy_signal": false, "relative_strength": -17.56087, "fair_value_gap": -1.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.3494, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.1% over one week, -2.4% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "Seeking Alpha", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "JD Supra", "count": 2}, {"label": "The National Law Review", "count": 2}, {"label": "MSN", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 11}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-9.1% over one week, -2.4% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026"}], "updated_at": "2026-07-16T11:51:33.279313+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}